Logo image of SABS

SAB BIOTHERAPEUTICS INC (SABS) Stock Fundamental Analysis

NASDAQ:SABS - Nasdaq - US78397T2024 - Common Stock

3.8  +0.13 (+3.54%)

Fundamental Rating

1

SABS gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. SABS may be in some trouble as it scores bad on both profitability and health. SABS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SABS had negative earnings in the past year.
In the past year SABS has reported a negative cash flow from operations.
SABS Yearly Net Income VS EBIT VS OCF VS FCFSABS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 20M -20M -40M

1.2 Ratios

The Return On Assets of SABS (-84.70%) is worse than 70.97% of its industry peers.
Looking at the Return On Equity, with a value of -123.48%, SABS is in line with its industry, outperforming 40.18% of the companies in the same industry.
Industry RankSector Rank
ROA -84.7%
ROE -123.48%
ROIC N/A
ROA(3y)-36.07%
ROA(5y)N/A
ROE(3y)-59.48%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SABS Yearly ROA, ROE, ROICSABS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 20 -20 40 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SABS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SABS Yearly Profit, Operating, Gross MarginsSABS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

3

2. Health

2.1 Basic Checks

SABS does not have a ROIC to compare to the WACC, probably because it is not profitable.
SABS has more shares outstanding than it did 1 year ago.
The debt/assets ratio for SABS has been reduced compared to a year ago.
SABS Yearly Shares OutstandingSABS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2M 4M 6M 8M
SABS Yearly Total Debt VS Total AssetsSABS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -4.34, we must say that SABS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.34, SABS is in line with its industry, outperforming 40.18% of the companies in the same industry.
A Debt/Equity ratio of 0.09 indicates that SABS is not too dependend on debt financing.
The Debt to Equity ratio of SABS (0.09) is worse than 65.84% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z -4.34
ROIC/WACCN/A
WACC10.86%
SABS Yearly LT Debt VS Equity VS FCFSABS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 3.69 indicates that SABS has no problem at all paying its short term obligations.
SABS has a Current ratio (3.69) which is comparable to the rest of the industry.
SABS has a Quick Ratio of 3.69. This indicates that SABS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.69, SABS is in line with its industry, outperforming 44.60% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.69
Quick Ratio 3.69
SABS Yearly Current Assets VS Current LiabilitesSABS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

SABS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -43.66%.
The Revenue for SABS has decreased by -63.05% in the past year. This is quite bad
SABS shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -65.65% yearly.
EPS 1Y (TTM)-43.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12%
Revenue 1Y (TTM)-63.05%
Revenue growth 3Y-65.65%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, SABS will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.69% on average per year.
SABS is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.35% yearly.
EPS Next Y48.44%
EPS Next 2Y25.87%
EPS Next 3Y17.69%
EPS Next 5YN/A
Revenue Next Year0.6%
Revenue Next 2Y-12.85%
Revenue Next 3Y-1.72%
Revenue Next 5Y-5.35%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SABS Yearly Revenue VS EstimatesSABS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
SABS Yearly EPS VS EstimatesSABS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SABS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SABS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SABS Price Earnings VS Forward Price EarningsSABS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SABS Per share dataSABS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as SABS's earnings are expected to grow with 17.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.87%
EPS Next 3Y17.69%

More info and screens

0

5. Dividend

5.1 Amount

SABS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAB BIOTHERAPEUTICS INC

NASDAQ:SABS (1/22/2025, 2:44:37 PM)

3.8

+0.13 (+3.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners33.88%
Inst Owner Change4.06%
Ins Owners18.53%
Ins Owner Change0%
Market Cap35.07M
Analysts83.64
Price Target12.65 (232.89%)
Short Float %0.49%
Short Ratio0.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)15.36%
Min EPS beat(2)-0.74%
Max EPS beat(2)31.46%
EPS beat(4)2
Avg EPS beat(4)-91.26%
Min EPS beat(4)-434.47%
Max EPS beat(4)38.73%
EPS beat(8)5
Avg EPS beat(8)-47.94%
EPS beat(12)8
Avg EPS beat(12)-60.12%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.25%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.56%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-13.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 23.18
P/FCF N/A
P/OCF N/A
P/B 0.95
P/tB 0.95
EV/EBITDA N/A
EPS(TTM)-5.89
EYN/A
EPS(NY)-3.03
Fwd EYN/A
FCF(TTM)-4.18
FCFYN/A
OCF(TTM)-4.14
OCFYN/A
SpS0.16
BVpS4
TBVpS4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -84.7%
ROE -123.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.07%
ROA(5y)N/A
ROE(3y)-59.48%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.19%
Cap/Sales 23.12%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.69
Quick Ratio 3.69
Altman-Z -4.34
F-Score4
WACC10.86%
ROIC/WACCN/A
Cap/Depr(3y)269.58%
Cap/Depr(5y)N/A
Cap/Sales(3y)11.95%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-43.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12%
EPS Next Y48.44%
EPS Next 2Y25.87%
EPS Next 3Y17.69%
EPS Next 5YN/A
Revenue 1Y (TTM)-63.05%
Revenue growth 3Y-65.65%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year0.6%
Revenue Next 2Y-12.85%
Revenue Next 3Y-1.72%
Revenue Next 5Y-5.35%
EBIT growth 1Y-92.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-19.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-97.3%
OCF growth 3YN/A
OCF growth 5YN/A